DON’T WAIT—
At the first clinical signs of CHF,
use VETMEDIN
When it comes to managing canine congestive heart failure (CHF) with the goal of improving and extending life, time matters. Though the early stages of heart disease can progress slowly, once clinical signs appear, immediate treatment is needed.1
VETMEDIN is FDA-approved for use as first-line treatment for dogs with mild, moderate, or severe CHF,2 so don’t wait to add it to your standard CHF treatment protocol. As a proven, versatile first-line therapy, VETMEDIN also may be used in conjunction with other CHF therapies, such as furosemide.2
Use VETMEDIN from the start of clinical signs, to help keep dogs going longer.1,3 VETMEDIN may be used during the initial acute phase of CHF. It works quickly and provides easy administration with no additional monitoring required.1,4
The American College of Veterinary Internal Medicine (ACVIM) now recommends VETMEDIN at the first appearance of CHF clinical signs. Click here for more information on the ACVIM Cardiology Panel Consensus Statement.
Important safety information
VETMEDIN should not be given in case of hypertrophic cardiomyopathy, aortic stenosis, or any other clinical condition where an augmentation of cardiac output is inappropriate for functional or anatomical reasons.
The safety of VETMEDIN has not been established in dogs with asymptomatic heart disease or in heart failure caused by etiologies other than atrioventricular valvular insufficiency or dilated cardiomyopathy.
The safe use of VETMEDIN has not been evaluated in dogs younger than 6 months of age, dogs with congenital heart defects, dogs with diabetes mellitus or other serious metabolic diseases, dogs used for breeding, or pregnant or lactating bitches. Use only in dogs with clinical evidence of heart failure.
References:
1. Lombard CW, Jöns O, Bussadori CM; for the VetSCOPE Study. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs. J Am Anim Hosp Assoc. 2006;42(4):249–261. 2. VETMEDIN® (pimobendan) Chewable Tablets [Freedom of Information Summary]. St. Joseph, MO: Boehringer Ingelheim Vetmedica, Inc.; 2007. 3. Häggström J, Boswood A, O’Grady M, et al. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study. J Vet Intern Med. 2008;22(5):1124–1135. 4. Gordon SG, Miller MW, Saunders AB. Pimobendan in heart failure—a silver bullet? J Am Anim Hosp Assoc. 2006;42(2):90–93. 5. Atkins C, Bonagura J, Ettinger S, et al. Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. J Vet Intern Med. 2009;23(6):1142–1150.
VETMEDIN is a registered trademark of Boehringer Ingelheim Vetmedica GmbH,
licensed to Boehringer Ingelheim Vetmedica, Inc.